AURINIA PHARMACEUTICALS INC (AUPH)
Health Care · Specialty biopharmaceuticals - autoimmune/nephrology · NASDAQ
Aurinia is a specialty pharma company commercializing LUPKYNIS, the first oral calcineurin inhibitor approved for lupus nephritis, with strong profitability and cash generation funding pipeline expansion.
What AURINIA PHARMACEUTICALS INC does
Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies for autoimmune diseases with high unmet medical needs. The company markets LUPKYNIS (voclosporin), the first FDA-approved oral therapy for active lupus nephritis, approved in January 2021. LUPKYNIS is sold directly in the US and through collaboration partner Otsuka in Japan, the EU, UK, and Switzerland. The company is also developing aritinercept, a dual inhibitor of BAFF and APRIL for autoimmune diseases.
Themes: ["lupus nephritis treatment","autoimmune disease therapeutics","rare disease / specialty pharma"]
Fundamentals
- Price$16.59 as of 2026-07-09 close
- Market cap$2.1B as of 2026-07-10
- 1-year return+97.7% as of 2026-07-09 close
- P/E7.16 as of 2026-07-10
- Net margin+100.0% as of 2026-07-10
- Gross margin+89.7% as of 2026-07-10
- ROE+64.5% as of 2026-07-10
- Debt / equity0.11 as of 2026-07-10
- Revenue growth (YoY)+20.6% as of 2026-07-10
- Revenue CAGR (3y)+28.3% SEC XBRL
- Beta1.39 as of 2026-07-10
Key risks (from latest filing)
["LUPKYNIS market penetration and competitive landscape: adoption depends on physician awareness, patient compliance, and competitive positioning against alternative immunosuppressive regimens","Development risk for aritinercept: clinical and regulatory success uncertain for this earlier-stage dual BAFF/APRIL inhibitor program","Otsuka partnership concentration: significant revenue from Otsuka collaboration in ex-US markets; performance and partnership stability are critical to international expansion"]
Competitors & peers
- Eli Lilly (LLY) - autoimmune disease therapeutics and lupus treatments
- AstraZeneca (AZN) - immunosuppressive and autoimmune therapies
- Vifor Pharma (VIFRF) - specialty nephrology and autoimmune treatments
- Kyprolis/Takeda - calcineurin inhibitor and immunosuppressive therapies
- Bristol Myers Squibb (BMY) - immunosuppressive agents
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.